Methods and formulations of using A1 adenosine receptor antagonists and P2x purinoceptor antagonists for the treatment and prevention of immune system disorders

A method for preventing or delaying the onset of an immune system disorder in a subject in need of such treatment, comprising administering to said subject a compound selected from the group consisting of:

• (a) A1 adenosine receptor antagonists;
• (b) P2X purinoceptor antagonists;
• and
• (c) a combination of at least one A1 adenosine receptor antagonist and at least one P2X purinoceptor antagonist;
• wherein said compound is administered in an amount effective to prevent or delay the onset of the immune system disorder that would occur in the absence of the administration.

A method for treating HIV infection or AIDS in a subject in need of such treatment, comprising administering to said subject a compound selected from the group consisting of:

• (a) A1 adenosine receptor antagonists;
• (b) P2X purinoceptor antagonists;
• and
• (c) a combination of at least one A1 adenosine receptor antagonist and at least one P2X purinoceptor antagonist;
• wherein said compound is administered in an amount effective to treat the HIV infection or AIDS.

A method for preventing or delaying the onset of HIV infection or AIDS in a subject in need of such treatment, comprising administering to said subject a compound selected from the group consisting of:

• (a) A1 adenosine receptor antagonists;
• (b) P2X purinoceptor antagonists;
• and
• (c) a combination of at least one A1 adenosine receptor antagonist and at least one P2X purinoceptor antagonist;
• wherein said compound is administered in an amount effective to prevent or delay the onset of the HIV infection or AIDS that would occur in the absence of the administration.

A method for treating adenosine deaminase deficiency-dependent severe immunodeficiency disease (ADA SCID) in a subject in need of such treatment, comprising administering to said subject a compound selected from the group consisting of:

• (a) A1 adenosine receptor antagonists;
• (b) P2X purinoceptor antagonists;
• and
• (c) a combination of at least one A1 adenosine receptor antagonist and at least one P2X purinoceptor antagonist;
• wherein said compound is administered in an amount effective to treat adenosine deaminase deficiency-dependent severe immunodeficiency disease (ADA SCID).

A method for preventing or delaying the onset of adenosine deaminase deficiency-dependent severe immunodeficiency disease (ADA SCID) in a subject in need of such treatment, comprising administering to said subject a compound selected from the group consisting of:

• (a) A1 adenosine receptor antagonists;
• (b) P2X purinoceptor antagonists;
• and
• (c) a combination of at least one A1 adenosine receptor antagonist and at least one P2X purinoceptor antagonist;
• wherein said compound is administered in an amount effective to prevent or delay the onset of the adenosine deaminase deficiency-dependent severe immunodeficiency disease (ADA SCID) that would occur in the absence of the administration.